GLP-1 drugs have become a major part of modern treatment for type 2 diabetes and obesity. These medicines mimic the hormone glucagon-like peptide-1 (GLP-1), helping regulate blood glucose, slow stomach emptying and increase feelings of fullness.
The list has also expanded in 2026, with a new oral medicine joining established injectable and tablet options.
GLP-1 Receptor Agonist Drug Names
Here is a quick GLP-1 medication list covering commonly used brand names and their active ingredients:
| GLP-1 Drug | Active Ingredient | Brand Name | Main Use | Form |
|---|---|---|---|---|
| Wegovy | Semaglutide | Wegovy | Obesity | Injection / Tablet |
| Ozempic | Semaglutide | Ozempic | Type 2 diabetes | Injection |
| Rybelsus | Semaglutide | Rybelsus | Type 2 diabetes | Tablet |
| Saxenda | Liraglutide | Saxenda | Obesity | Injection |
| Victoza | Liraglutide | Victoza | Type 2 diabetes | Injection |
| Trulicity | Dulaglutide | Trulicity | Type 2 diabetes | Injection |
| Byetta | Exenatide | Byetta | Type 2 diabetes | Injection |
| Bydureon BCise | Exenatide | Bydureon BCise | Type 2 diabetes | Injection |
| Adlyxin | Lixisenatide | Adlyxin | Type 2 diabetes | Injection |
| Foundayo | Orforglipron | Foundayo | Obesity | Oral tablet |
The FDA identifies medicines containing semaglutide, liraglutide and other agents in this class as GLP-1 receptor agonists.
New GLP-1 Drug: Foundayo
One of the biggest developments in the 2026 GLP-1 drug market is Foundayo (orforglipron) from Eli Lilly.
The FDA approved Foundayo on April 1, 2026, for chronic weight management in adults with obesity or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. It is a once-daily oral GLP-1 receptor agonist and does not need to be taken on an empty stomach.
This makes Foundayo particularly notable because the obesity market has historically been dominated by injectable GLP-1 treatments.
Wegovy Gets a Higher Dose
Another major 2026 development is Wegovy HD, a 7.2 mg dose of semaglutide injection. The FDA approved the higher-dose formulation in March 2026 for certain adults with obesity or overweight and a weight-related condition.
FDA records also list Wegovy as both an injection and oral tablet, reflecting the rapid expansion of semaglutide formulations.
GLP-1 vs GIP/GLP-1 Medicines
When searching for a GLP-1 agonist list, it is important to distinguish pure GLP-1 receptor agonists from dual-action medicines.
Zepbound and Mounjaro, for example, contain tirzepatide, which activates both GIP and GLP-1 receptors. They are therefore generally described as GIP/GLP-1 receptor agonists, rather than GLP-1-only drugs.
2026 GLP-1 Drug Landscape
The class is changing rapidly. At the same time as new oral options arrive, the FDA has also taken action concerning compounded GLP-1 products, proposing to exclude semaglutide, tirzepatide and liraglutide from its 503B bulk-drug list after finding no clinical need for outsourcing facilities to compound them from bulk substances.
Bottom Line
The major GLP-1 receptor agonist brand names include Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Trulicity, Byetta, Bydureon BCise, Adlyxin and the newly approved Foundayo. However, approval, availability and indications vary by country and product.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 medicines are prescription drugs and should be used only under appropriate medical supervision.
